News

News

DiogenX appoints Dr. Klara Owen as Chief Medical Officer

November 12, 2024

DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors

September 9, 2024

DiogenX strengthens Executive Committee with Hélène Sicard joining as Chief Development Officer

July 25, 2024

Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developinga first-in-class regenerative treatment for type 1 diabetes

October 31, 2023

DiogenX raises €27.5M Series A financing to advance its first-in-class regenerative treatment for type 1 diabetes into clinical trial

May 10, 2023

DiogenX Raises €4.5M in Seed Financing from Advent France Biotechnology, Boehringer Ingelheim Venture Fund and JDRF T1D Fund

June 16, 2020

Events

12/11/2024

DiogenX appoints Dr. Klara Owen as Chief Medical Officer

09/09/2024

DiogenX welcomes Eleanor L. Ramos as independent member of its Board of Directors

25/07/2024

DiogenX strengthens Executive Committee with Hélène Sicard joining as Chief Development Officer

31/10/2023

Sunstone Life Science Ventures Fund IV invests in DiogenX, a biotech company developinga first-in-class regenerative treatment for type 1 diabetes

DIOGENX

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.

Head office

180 avenue du Prado

13008 Marseille

Institut de biologie Valrose

Parc Valrose – Centre de Biochimie

06108 Nice cedex 2 France